Uncategorized
Aerpio begins dosing in trial of diabetic retinopathy treatment
Patient dosing is underway in the TIME-2b clinical trial of AKB-9778 to treat moderate to severe nonproliferative diabetic retinopathy, according to a press release from Aerpio Pharmaceuticals.The double-masked, placebo-controlled, multicenter phase 2b trial will include 150 participants with diabetic retinopathy receiving AKB-9778 15 mg subcutaneously once daily, the same drug twice daily or a placebo for 12 months.